ESR1 and breast carcinoma: We employed the luminal A, ER-positive/HER2-negative breast cancer cell line MCF7, which retains E-cadherin expression19, and that expresses higher levels of AXIN2 compared to other ER-positive/HER2-negative breast cancer cells, such as CAMA1 and T47D (Supplementary Fig. S2).